New insulin study aims to tame blood sugar in chinese diabetes patients
NCT ID NCT05002933
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a long-acting insulin called insulin glargine U300 in 570 Chinese adults with type 2 diabetes whose blood sugar was not well controlled. Some participants had never used insulin before, while others switched from another basal insulin. The main goal was to see how much their average blood sugar (HbA1c) dropped over 24 weeks, with a 12-week extension for longer-term safety. The study was completed and provides real-world data on this insulin's effectiveness and safety in this population.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- insulin glargine U300 (a long-acting insulin)
- What this could lead to
- If successful, this could confirm that insulin glargine U300 helps Chinese patients with type 2 diabetes better control their blood sugar with a manageable safety profile.
- What could go wrong
- This is a single-arm, open-label study with no placebo or comparison group, so results may be less reliable. It only lasts 6-9 months, so long-term benefits or risks are not assessed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Investigational Sites
China, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a blood flow 'Tourniquet' workout repair diabetic nerve damage?
- Could a common diabetes drug weaken your bones?
- Can a spice and a mindset shift ease diabetic nerve pain?
- Ancient wisdom meets modern care: could chinese medicine boost diabetes Self-Management?
- Could a peptide injection help rebuild Insulin-Making cells?
- A pill for diabetes? new oral drug aims to rival injections